Table 2.
Pulmonary Arterial Hypertension Therapy Received by World Symposium on Pulmonary Hypertension Group 1 and 3 Patients
| All Patients | Cohort A | Cohort B | ||
|---|---|---|---|---|
| WSPH Group 1 | (n = 308) 100% | (n = 165) 53.6% | (n = 143) 46.4% | P Value |
| Received PAH therapy | 280 (90.9) | 149 (90.3) | 131 (91.6) | 0.876 |
| Therapy type* | <0.001 | |||
| Single | 99 (35.4) | 60 (40.2) | 39 (29.8) | |
| PDE5I/sGCS† | 63 (63.6) | 31 (51.7) | 32 (82.1) | |
| ERA† | 28 (28.3) | 22 (36.7) | 6 (15.4) | |
| PCA† | 8 (8.1) | 7 (11.6) | 1 (2.5) | |
| Upfront dual | 65 (23.2) | 15 (10.1) | 50 (38.2) | |
| PDE5I + ERA (vs. PDE5I + PCA or ERA + PCA)‡ | 53 (81.5) | 8 (53.3) | 45 (90.0) | |
| Sequential dual | 60 (21.4) | 42 (28.2) | 18 (13.7) | |
| PDE5I + ERA (vs. PDE5I + PCA or ERA + PCA)§ | 45 (75.0) | 30 (71.4) | 15 (53.3) | |
| Triple (PDE5I + ERA + PCA) | 56 (20.0) | 32 (21.5) | 24 (18.3) |
| WSPH Group 3 | (n = 151) 100% | (n = 64) 42.4% | (n = 87) 57.6% | |
|---|---|---|---|---|
| Received PAH therapy | 117 (77.5) | 52 (81.3) | 65 (74.7) | 0.144 |
| Therapy type* | 0.693 | |||
| Single | 81 (69.2) | 35 (67.3) | 46 (70.8) | |
| PDE5I/sGCS† | 68 (84.0) | 27 (77.2) | 41 (89.1) | |
| ERA† | 11 (13.6) | 6 (17.1) | 5 (10.9) | |
| PCA† | 2 (2.4) | 2 (5.7) | 0 (0.0) | |
| Upfront dual | 10 (8.6) | 5 (9.6) | 5 (7.7) | |
| PDE5I + ERA (vs. PDE5I + PCA or ERA + PCA)‡ | 7 (70.0) | 4 (80.0) | 3 (60.0) | |
| Sequential dual | 16 (13.7) | 6 (11.5) | 10 (15.4) | |
| PDE5I + ERA (vs. PDE5I + PCA or ERA + PCA)§ | 13 (81.3) | 6 (100.0) | 7 (70.0) | |
| Triple (PDE5I + ERA + PCA) | 10 (8.6) | 6 (11.5) | 4 (6.2) |
Definition of abbreviations: ERA = endothelin receptor antagonist; PAH = pulmonary arterial hypertension; PCA = prostacyclin analogue; PDE5I = phosphodiesterase type 5 inhibitor; sGCS = soluble guanylate cyclase stimulator; WSPH = World Symposium on Pulmonary Hypertension.
For the Age variable (continuous, skewed variable), data are presented as median (lower quartile Q1 - upper quartile Q3).
For all other variables (categorical variables), data are presented as percentage.
Among those who received PAH therapy.
Among those who received monotherapy.
Among those who received upfront dual therapy.
Among those who received sequential dual therapy.